GGrantIndex
← Search

Biomedical Tech

$25,235P30FY2013CANIH

University Of California At Davis, Davis CA

Investigators

Linked publications, trials & patents

Paper 39725713Paper 39620216Paper 39616300Paper 39488208Paper 39453739Paper 39440945Paper 39384967Paper 39383000Paper 39350111Paper 39345479Paper 39345391Paper 39257973Paper 39252929Paper 39217266Paper 39177582Paper 39168154Paper 39108503Paper 39103353Paper 39056190Paper 39046599Paper 39012466Paper 38990223Paper 38979288Paper 38969563Paper 38947002Paper 38885336Paper 38877132Paper 38865710Paper 38843382Paper 38826195Paper 38803393Paper 38798575Paper 38780011Trial NCT07304011Trial NCT07258446Trial NCT07209215Trial NCT07189195Trial NCT07145112Trial NCT06905509Trial NCT06854159Trial NCT06211335Trial NCT06178354Trial NCT06173362Trial NCT06173349Trial NCT06103682Trial NCT06103669Trial NCT06067776Trial NCT05967533Trial NCT05843448Trial NCT05600686Trial NCT05479578Trial NCT05110781Trial NCT05101356Trial NCT05052528Trial NCT04964505Trial NCT04905810Trial NCT04856189Trial NCT04716699Trial NCT04587687Trial NCT04578600Trial NCT04552704Trial NCT04450173Trial NCT04410302Trial NCT04186988Trial NCT04050085Trial NCT04030559Trial NCT03695250Trial NCT03359460Trial NCT03299088Trial NCT03164486Trial NCT03123978Trial NCT02997761Trial NCT02935205Trial NCT02823990Trial NCT02807805Trial NCT02569723Trial NCT02400814Trial NCT02364609Trial NCT02348255Trial NCT02339168Trial NCT02178241Trial NCT02077998Trial NCT01924260Trial NCT01923337Trial NCT01911507Trial NCT01008566Trial NCT00918645Trial NCT00810719Trial NCT00804310Trial NCT00795665Trial NCT00628654Trial NCT00467077Trial NCT00408499Trial NCT00390429Trial NCT00389922Trial NCT00388115Trial NCT00388089Trial NCT00387660Trial NCT00387322Trial NCT00376727

Abstract

The Biomedical Technology Program harnesses the expertise of scientists and engineers in collaboration with clinicians to develop new technologies, instruments, methods and algorithms that can be used for cancer screening, detection, diagnosis, treatment or treatment monitoring. The program draws primarily on science and engineering expertise from four key components, the Departments of Biomedical Engineering and Radiology at UC Davis, the NSF Center for Biophotonics Science and Technology (CBST), and the Lawrence Livermore National Laboratory (LLNL). In addition, clinical members of the program, from both the Medical School and School of Veterinary Medicine, with an expertise in radiology, radiafion oncology and surgery, are critical in guiding and supporting translational activities. Core themes of the program are technologies for cancer research and diagnosis, whole-body and organ imaging technologies, therapeutic technologies, biomarker discovery, and biosensors. These technologies span research, preclinical and clinical applications and include active collaborations with industry. They also cover spatial scales ranging from single molecules, through cells and tissues, to the whole-body level. The goals of the Biomedical Technology Program include: 1) create an environment that encourages development of technologies to address critical questions in cancer research and cancer care, 2) foster interactions between engineers, physicists and chemists with cancer biologists and physicians to guide the development process, 3) catalyze interactions to enable testing and validation of these technologies in pre-clinical models of cancer and in clinical settings; 4) make technologies accessible through collaboration with cancer researchers and clinicians in other Cancer Center programs or via the shared resources as appropriate and 5) encourage interactions with industry that can lead to broader dissemination and adoption of these technologies. The program has 36 members from 10 different departments of UC Davis and 6 departments of LLNL. It has 18 NCl-funded projects for $3.2 million ADC (total peer-reviewed funding, $8.8 million ADC). The group has 869 publications for the last funding period; 22% are inter-programmatic and 11% are intra-programmatic.

View original record on NIH RePORTER →